ライフサイエンスコーパス: DOTATOC

1 r and healthy muscle) was estimated on 177Lu-DOTATOC SPECT/CT scans of 15 patients affected by NET wi

2 68Ga-DOTATOC is an excellent specific ligand for this hSSTr2

3 68Ga-DOTATOC PET/CT detected additional hepatic and/or extrah

4 d in the protocol of comparison between 68Ga-DOTATOC PET/CT and CT and/or MRI.

5 omatostatin receptor subtype 2 (hSSTr2)-68Ga-DOTATOC reporter system has several attractive features

6 More important, 68Ga-DOTATOC PET/CT impacted our treatment decision in more t

7 s, a rapid internalized accumulation of 68Ga-DOTATOC in the SSTr2-expressing cells, and a rapid excre

8 Small-animal PET of 68Ga-DOTATOC in tumor-bearing mice demonstrated that the in v

9 The in vivo uptake of 68Ga-DOTATOC, at 2 h after injection, was low in all organs e

10 Overall, 68Ga-DOTATOC PET/CT altered our treatment decision based on C

11 In all 52 patients, 68Ga-DOTATOC PET/CT demonstrated pathologically increased upt

12 tients with unknown primary tumor site, 68Ga-DOTATOC PET/CT visualized the primary tumor region (jeju

13 In this study, 68Ga-DOTATOC PET/CT proved clearly superior to CT and/or MRI

14 d elsewhere and consecutively underwent 68Ga-DOTATOC PET/CT in our institution.

15 tumor-bearing mice were evaluated with 68Ga-DOTATOC PET studies.

16 In particular, if 90Y-DOTATOC is used with liver NET metastases, the proposed

17 s mellitus risk was higher before than after DOTATOC (estimate, 0.0032; P < 0.001), and overall survi

18 cted the somatostatin receptor imaging agent DOTATOC as the foundation for developing a dual-labeled

19 using the DOTA-derived somatostatin analogs DOTATOC or DOTATATE for PET.

20 Because DOTATOC has undergone extensive clinical testing, this h

21 Cobalt-labeled DOTATATE, DOTATOC, and DOTANOC were prepared with (57)Co or (58m)C

22 after the administration of (177)Lu-DOTATATE/DOTATOC provides a 3-dimensional dose map and can be use

23 d benefit of treatment with (177)Lu-DOTATATE/DOTATOC.

24 P values of 0.004 and 0.008) than for (68)Ga-DOTATOC (1.9, with an interquartile range of 1.4-2.9).

25 ngle 150-MBq intravenous injection of (68)Ga-DOTATOC (15 mug of peptide) and 2 single 150-MBq intrave

26 compared with the reference compound, (68)Ga-DOTATOC (an sst receptor agonist), in PET imaging.

27 high-yield preparation of injectable (68)Ga-DOTATOC (or other (68)Ga-labeled radiopharmaceuticals) t

28 , respectively, and 59% for 15 mug of (68)Ga-DOTATOC (P < 0.001).

29 compare the uptake of the PET tracers (68)Ga-DOTATOC and (64)Cu-DOTATATE in large arteries, in the as

30 neuroendocrine tumors underwent both (68)Ga-DOTATOC and (64)Cu-DOTATATE PET/CT scans, in random orde

31 ncologic patients, vascular uptake of (68)Ga-DOTATOC and (64)Cu-DOTATATE was found, with highest upta

32 pared with whole-body images for both (68)Ga-DOTATOC and (68)Ga DOTATATE.

33 (68)Ga-DOTATOC and (68)Ga-DOTATATE are 2 radiolabeled somatosta

34 (68)Ga-DOTATOC and (68)Ga-DOTATATE are radiolabeled somatostati

35 (68)Ga-DOTATOC and (68)Ga-DOTATATE are suited equally well for

36 tumor volume, or SSTR volume between (68)Ga-DOTATOC and (68)Ga-DOTATATE at any time point.

37 litatively compare the performance of (68)Ga-DOTATOC and (68)Ga-DOTATATE in the context of subsequent

38 body PET/CT at 1 h after injection of (68)Ga-DOTATOC and (68)Ga-DOTATATE on consecutive days.

39 body PET/CT at 1 h after injection of (68)Ga-DOTATOC and (68)Ga-DOTATATE on consecutive days.

40 ope, 0.71) and 0.92 (slope, 0.74) for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

41 ges than in the whole-body images for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

42 ope, 0.81) and 0.97 (slope, 0.88) for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

43 ope, 0.81) and 0.97 (slope, 0.88) for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

44 The radiochemical purity of both (68)Ga-DOTATOC and (68)Ga-PSMA-HBED-CC determined by high-perfo

45 (68)Ga-DOTATOC and (68)Ga-PSMA-HBED-CC investigational radiopha

46 Imaging with (68)Ga-DOTATOC appears promising especially in poorly different

47 liver ratio was marginally higher for (68)Ga-DOTATOC at the 3-h time point (P = 0.037).

48 taanalysis summarizes the efficacy of (68)Ga-DOTATOC for several distinct indications and is intended

49 ons were found by (64)Cu-DOTATATE and (68)Ga-DOTATOC in 13 and 3 patients, respectively.

50 mance of (64)Cu-DOTATATE with that of (68)Ga-DOTATOC in NET patients.

51 n:(64)Cu-DOTATATE has advantages over (68)Ga-DOTATOC in the detection of lesions in NET patients.

52 OTATATE was significantly higher than (68)Ga-DOTATOC in the vascular regions both when calculated as

53 was the same for (64)Cu-DOTATATE and (68)Ga-DOTATOC in this cohort, significantly more lesions were

54 administration of (68)Ga-DOTATATE and (68)Ga-DOTATOC is 2.1 mSv for both tracers.

55 Conclusion:(68)Ga-DOTATOC is useful for evaluating the presence and extent

56 tment, the NET patients injected with (68)Ga-DOTATOC or (123)I MIBG emitted an average EDR-1m roughly

57 often slightly greater than those for (68)Ga-DOTATOC or (68)Ga-DOTANOC but less than those for (111)I

58 rom healthy tissues were estimated on (68)Ga-DOTATOC PET scans of 11 meningioma patients and 12 HGG p

59 tide was assessed quantitatively with (68)Ga-DOTATOC PET, with the finding that increased occupancy r

60 (68)Ga-DOTATOC PET/CT (CT without contrast, low-dose) was perfo

61 rmed by (18)F-FDG PET/CT (LC and MM), (68)Ga-DOTATOC PET/CT (GEP NET), and (68)Ga-labeled prostate-sp

62 scanned with both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT and compared on a head-to-head basis.

63 scanned with both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT and compared on a head-to-head basis.

64 Visual assessment of (68)Ga-DOTATOC PET/CT images used a 4-point scale for classific

65 ET and unknown primary site underwent (68)Ga-DOTATOC PET/CT in a single-site prospective study.

66 This study evaluated the impact of (68)Ga-DOTATOC PET/CT in detecting recurrence or metastases in

67 Conclusion:(68)Ga-DOTATOC PET/CT is an effective modality in the localizat

68 detected on both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT scans, whereas an additional 68 lesions w

69 detected on both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT scans, whereas an additional 68 lesions w

70 (68)Ga-DOTATOC PET/CT should be considered in the case of negat

71 ministered activity was 122 MBq in 53 (68)Ga-DOTATOC PET/CT studies, 198 MBq in 15 (18)F-FDOPA PET/CT

72 A scan was classified unconfirmed if (68)Ga-DOTATOC PET/CT suggested a primary, however, no histolog

73 The (68)Ga-DOTATOC PET/CT was considered true-positive if the posit

74 The rate of positive (68)Ga-DOTATOC PET/CT was significantly higher in poorly differ

75 (68)Ga-DOTATOC PET/CT was true-positive in 5 patients (10 tumor

76 e values for (68)Ga-OPS202 PET/CT and (68)Ga-DOTATOC PET/CT were similar ( approximately 98%).

77 n patients with tumor localization on (68)Ga-DOTATOC PET/CT, but differences were not significant.

78 tients with true-positive findings on (68)Ga-DOTATOC PET/CT, CT alone but not ultrasound identified 2

79 the (68)Ga-OPS202 scans than for the (68)Ga-DOTATOC scan: the median of the mean tumor-to-background

80 (68)Ga-DOTATOC showed 26 lesions not found on (64)Cu-DOTATATE,

81 (68)Ga-DOTATOC uptake was higher in mediastinal blood pool at t

82 PCA correlated with(18)F-FDG uptake, (68)Ga-DOTATOC uptake, and (68)Ga-PSMA uptake, respectively, an

83 Although (68)Ga-DOTATOC would seem to be useful in evaluating patients w

84 ith novel somatostatin analogs (e.g., (68)Ga-DOTATOC, (68)Ga-DOTATATE, (68)Ga-DOTANOC, and (64)Cu-DOT

85 (68)Ga-labeled sstr agonists, such as (68)Ga-DOTATOC, (68)Ga-DOTATATE, and [(68)Ga-DOTA,1-Nal(3)]octr

86 undergoing PET/CT with (18)F-FDOPA or (68)Ga-DOTATOC, a somatostatin analog.

87 (68)Ga-DOTATOC, a somatostatin receptor-targeted ligand, has be

88 0.003 mSv/MBq for (68)Ga-DOTATATE and (68)Ga-DOTATOC, mainly because of higher uptake in liver and ki

89 TATATE showed 42 lesions not found on (68)Ga-DOTATOC, of which 33 were found to be true-positive on f

90 Uptake of (64)Cu-DOTATATE, but not of (68)Ga-DOTATOC, was correlated with cardiovascular risk factors

91 0 tumor lesions, but in both patients (68)Ga-DOTATOC-PET/CT revealed further tumor lesions not detect

92 lesion was found corresponding to the (68)Ga-DOTATOC-positive site.

93 pancy level using the PET radiotracer (68)Ga-DOTATOC.

94 whereas no association was found with (68)Ga-DOTATOC.

95 (177)Lu-DOTATATE and (68)Ga-DOTATOC/(68)Ga-DOTATATE are used, respectively, for PRRT

96 itivity with the antagonist than with (68)Ga-DOTATOC: 94% and 88% for 50 and 15 mug of (68)Ga-OPS202,

97 men magnetic resonance imaging and gallium68-DOTATOC positron emission tomography scan demonstrated t

98 irst candidate is represented by 90Y-labeled DOTATOC, a compound commonly used today for peptide radi

99 Recently, (57)Co-labeled DOTATOC, an octreotide analog, was shown to have the hig

100 nction with the production of (68)Ga-labeled DOTATOC and Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-HBED-CC)

101 tion of (177)Lu-DOTATATE (n = 22) or (177)Lu-DOTATOC (n = 7).

102 (90)Y-DOTATOC and (177)Lu-DOTATOC are promising tools for treating progressive unr

103 were treated with (90)Y-DOTATOC and (177)Lu-DOTATOC until tumor progression or permanent toxicity oc

104 DOTA(0),Tyr(3)]octreotide ((90)Y- or (177)Lu-DOTATOC, respectively) and [(177)Lu-DOTA(0),Tyr(3)]octre

105 eptide therapy with (90)Y-DOTATOC or (177)Lu-DOTATOC.

106 MIBG) and (90)Y-DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) have been used as radiotherapeutic agents for t

107 the radiolabeling efficiency and efficacy of DOTATOC, providing yields of greater than 99% (decay-cor

108 (111)In-octreotide (2 papers, sensitivity of DOTATOC on a per-lesion basis was 100%, for (111)In-octr

109 tumors (NET) requires study of the uptake of DOTATOC and its time evolution both in tumors and in hea

110 Uptake of DOTATOC on NETs maximized at about 24 h after injection.

111 cal extracranial tumor showed high uptake of DOTATOC.

112 post-processed (68)Ga was used to radiolabel DOTATOC in combination with high-purity water and variou

113 processed eluate has been used to radiolabel DOTATOC in yields of approximately 97% +/- 0.25% at 80 d

114 57, using 92% of the maximum tolerated (90)Y-DOTATOC activity supplemented with 76% of the maximum to

115 etric organ values for (131)I-MIBG and (90)Y-DOTATOC along with critical organ-dose limits.

116 (90)Y-DOTATOC and (177)Lu-DOTATOC are promising tools for trea

117 esectable meningioma were treated with (90)Y-DOTATOC and (177)Lu-DOTATOC until tumor progression or p

118 tes mellitus, including 47 cases after (90)Y-DOTATOC and 25 cases after combined treatment.

119 g is 3 cycles of 1.85 GBq/m(2)/dose of (90)Y-DOTATOC coadministered with amino acids.

120 Combining (131)I-MIBG and (90)Y-DOTATOC for radiotherapy of neuroendocrine tumors can si

121 y applied doses were 7,400 MBq/m(2) of (90)Y-DOTATOC in 2 fractions.

122 paper reports a study of the uptake of (90)Y-DOTATOC in meningiomas and high-grade gliomas (HGGs) and

123 Uptake of (90)Y-DOTATOC in meningiomas was high in all studied patients.

124 ide receptor radionuclide therapy with (90)Y-DOTATOC is safe in children and young adults and demonst

125 tor-targeted radionuclide therapy with (90)Y-DOTATOC may be a therapeutic option.

126 somatostatin radiopeptide therapy with (90)Y-DOTATOC or (177)Lu-DOTATOC.

127 (90)Y-DOTATOC therapy is feasible and may represent a promisin

128 tudy was to conduct a phase I trial of (90)Y-DOTATOC to determine the dose-toxicity profile in childr

129 fore and at 2 months after intravenous (90)Y-DOTATOC treatment.

130 f the tumor-dose ratio, defined as the (90)Y-DOTATOC tumor dose per megabecquerel divided by the (131

131 etermine the highest tolerable dose of (90)Y-DOTATOC, with administered activities of 1.11, 1.48, and

132 with respect to either (131)I-MIBG or (90)Y-DOTATOC.

133 isk profile were treated with systemic (90)Y-DOTATOC.

134 e, 2-24 y) received at least 1 dose of (90)Y-DOTATOC; diagnoses included neuroblastoma, embryonal and